S. Murata, “The Change in Neutrophil-to-lymphocyte Ratio after Initiation of Nivolumab Monotherapy May be a Strong Marker of Response and Predictor of Prognosis in Advanced Non-small Cell Lung Carcinoma”, apjcc, vol. 7, no. 1, pp. 191-196, Mar. 2022.